Trends in insurance coverage for adolescent reduction mammaplasty

Am J Surg. 2022 Oct;224(4):1068-1073. doi: 10.1016/j.amjsurg.2022.07.030. Epub 2022 Aug 5.

Abstract

Background: Reduction mammaplasty is an effective intervention for symptomatic macromastia. Studies of insurance policy criteria for adult patients have demonstrated nonuniformity. This study assesses trends in insurance preauthorization for reduction mammaplasty in the adolescent population.

Methods: A retrospective cohort study of patients aged ≤18 years at a pediatric breast clinic between January 1, 2010 and December 31, 2020. Demographic information and clinical variables submitted to insurers were analyzed, as well as third-party payer company, provider network type, and preauthorization criteria.

Results: 249 preauthorization requests were studied, with an approval rate of 79.5%. Submissions increased from 6 in 2010 to 59 in 2020. Variables deemed significantly associated with preauthorization denial included submission before 2015 (OR 2.04, 95% CI 1.04-3.95, p = .038), billing zip code median income <$60,000 (OR 2.11, 95% CI 1.12-3.98 p = .02), predicted resection mass below Schnur Sliding Scale threshold (OR 1.97, 95% CI 1.01-3.83 p = .047), and insurance company.

Conclusions: Insurance criteria for preauthorization of reduction mammaplasty in adolescents differ from adults, are not supported by clinical studies, and may exclude low-income patients from receiving care.

MeSH terms

  • Adolescent
  • Adult
  • Breast / surgery
  • Child
  • Female
  • Humans
  • Hypertrophy / surgery
  • Insurance Coverage
  • Mammaplasty*
  • Retrospective Studies